LODOSYN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LODOSYN (LODOSYN).
Lodosyn (carbidopa) is a peripheral decarboxylase inhibitor that inhibits the conversion of levodopa to dopamine outside the central nervous system. By blocking aromatic L-amino acid decarboxylase (AAAD) in peripheral tissues, it increases the amount of levodopa available to cross the blood-brain barrier, enhancing central dopamine levels and reducing peripheral side effects such as nausea and vomiting.
| Metabolism | Carbidopa is metabolized primarily via conjugation (glucuronidation) and oxidation, with 50-60% of the dose excreted unchanged in urine. The major metabolite is 3-O-methylcarbidopa, formed by catechol-O-methyltransferase (COMT). |
| Excretion | Renal: 70% unchanged; 30% as O-methylated and sulfate conjugates. Biliary/fecal: <5%. |
| Half-life | 1.5–2.5 hours in adults; prolonged in renal impairment (up to 6–8 hours). |
| Protein binding | 40–50%, primarily to albumin. |
| Volume of Distribution | 1.0–1.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 60–75% (first-pass metabolism). IV: 100%. |
| Onset of Action | Oral: 45–60 minutes; IV: 15–30 minutes. |
| Duration of Action | Oral: 4–6 hours; IV: 2–4 hours. Shorter with rapid renal clearance. |
250 mg orally twice daily, in combination with levodopa/carbidopa.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use caution with GFR <30 mL/min. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not established; off-label use not recommended. |
| Geriatric use | Start at lower end of dosing range; monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LODOSYN (LODOSYN).
| Breastfeeding | Carbidopa is excreted in human milk, but M/P ratio not established. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Lodosyn (carbidopa) is used in combination with levodopa. There are no adequate well-controlled studies in pregnant women. Animal reproduction studies have shown fetal abnormalities at high doses. The risk is likely minimal during first trimester, but potential benefits must outweigh risks. Second and third trimester risks are unknown; avoid use unless clearly necessary. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to carbidopa or any component","Concurrent use with nonselective MAO inhibitors (e.g., phenelzine, tranylcypromine; risk of hypertensive crisis)","Narrow-angle glaucoma (relative, due to risk of increased intraocular pressure)","Suspicion of melanoma (due to potential activation of malignant melanoma)","Severe psychotic disorders (relative)"]
| Precautions | ["Risk of neuroleptic malignant syndrome (NMS) upon abrupt withdrawal or dose reduction","May cause dyskinesias or psychiatric disturbances (e.g., hallucinations, depression) due to increased central dopamine","Must be used with levodopa; not effective alone","Caution in patients with cardiovascular disease, peptic ulcer disease, or glaucoma","May affect glucose tolerance; monitor diabetic patients","May cause false positive urine ketone tests"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of dyskinesia. Fetal monitoring includes ultrasound for growth and development if prolonged use. No specific routine monitoring required outside standard prenatal care. |
| Fertility Effects | No specific human data on fertility. Animal studies have not shown significant effects. However, levodopa may affect prolactin levels, potentially impacting fertility. Use with caution in women planning pregnancy. |